
ADI invites Biogen to present aducanumab data
This 75-minute webinar will present the data for Biogen’s investigational drug aducanumab, which if approved, would be the first disease-modifying treatment for Alzheimer’s disease.
News, conferences, events, blogs and updates from across the field of dementia and the work of Alzheimer's Disease International.
This 75-minute webinar will present the data for Biogen’s investigational drug aducanumab, which if approved, would be the first disease-modifying treatment for Alzheimer’s disease.
Alzheimer’s Disease International (ADI) launches the world’s most comprehensive report on dementia-related design and the built environment.
Though Italy's National Dementia Plan was first approved in 2014, this is the first time that the plan will receive funding by the Italian government.
ADI 2020 will take place from Thursday, 10 December until Saturday, 12 December and feature over 1,500 delegates from around the world.
People with dementia must be included in the priority groups for new COVID-19 vaccines, both in care homes and at home, say Alzheimer’s Disease International People with dementia are being disproportionately affected by COVID-19 and amongst most vulnerable in society Recent studies show COVID-19 deaths disproportionately affecting people with dementia;…
Emma Cariaga and Ginny Warr of British Land explore what inclusive design means for older people and for business growth. They look at Canada Water, where British Land is creating London’s first new town centre in over 100 years, and at activities across the company’s wider portfolio.
A new policy briefing, co-authored by ADI, thoroughly examines dementia care policy in Qatar.
A new data platform AD Workbench was launched by the Alzheimer’s Disease Data Initiative (ADDI).
Promising results from a clinical trial have been published in the peer-reviewed journal of the Alzheimer’s Association.
The US Food and Drug Administration has reviewed clinical trial data for Biogen’s drug aducanumab, which aims to treat cognitive and functional decline in Alzheimer’s disease.